[1]
Pondel, K., Kawałko, K., Bielewicz, K., Chmura, A. and Karaś, A. 2022. Effect of glucagon-like peptide-1 (GLP-1) agonists on the example of semaglutide on the cardiovascular system and their role in the treatment of obesity. Journal of Education, Health and Sport. 12, 9 (Aug. 2022), 55–60. DOI:https://doi.org/10.12775/JEHS.2022.12.09.007.